Medicortex Finland Oy: Clinical Trial Extended for Detection of Mild Traumatic Brain Injury
Medicortex Finland today announced that the Ethics Committee approved an additional site in the second clinical trial of ProbTBI™, a diagnostic kit for mild Traumatic Brain Injury (TBI) detection. Accelerated recruitment of patients will be performed in the central hospitals of Turku, Pori and Vaasa in Finland during the next few months.
The clinical trial is being conducted in Finland at three central hospital sites with first level emergency departments and high expertise in the TBI management. Patients with suspected mild TBI or concussion will be studied with respect to their specific biomarker signature in their bodily fluids and they will be compared to control patients with orthopedic injury and to healthy controls. Among the first target of 60 subjects, all healthy controls and more than half of the injured patients have been recruited until now. In the second stage the number of patients is extendable to 160. The study is posted in a public database where the status and progression are kept updated (www.ClinicalTrials.gov, NCT03306563).
"ProbTBI™ will be a highly innovative novel diagnostic kit for rapid detection of TBI and concussion. It is now further developed and evidenced in the ongoing clinical trial" said Dr. Adrian Harel, CEO of Medicortex. “Involvement of the third hospital will speed up the recruitment of patients and it will guarantee us adequate population for the next extended stage as we are now covering the entire Western Finland” Dr. Harel adds.
Dr. Mårten Kvist, Medical Director of Medicortex says: "A diagnostic tool for rapid detection of TBI is truly awaited and it will satisfy an urgent need to considerably improve the detection of brain injury in patients who are suffering a head injury without self-evident symptoms of brain damage.” and he adds that “By including sufficient number of patients in the clinical study Medicortex will justify the scientific and statistic strength of its biomarker detection assay.”
Medicortex Finland Oy is engaged in the development of first-of-its-kind diagnostic kit for rapid detection of concussion and mild TBI. The Company has the technology to capture biomarkers from noninvasive body fluid samples and to develop them into an affordable diagnostic tool. The patent portfolio held by Medicortex grants safety to develop the products. More information about TBI and its detection is available on Company's website at www.medicortex.fi
Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence and severity of a head injury. Once the company completes the kit development, its next goal will be to develop an innovative drug to halt the progression of brain injury.
Key words: brain injury, head injury, concussion, diagnostics, TBI, early detection, trauma, clinical trial
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
MyHeritage er oppnevnt som hovedsponsor for the Eurovision Song Contest 201926.9.2018 12:09 | Pressemelding
MyHeritage, det ledende, globale slektshistorie og DNA-selskapet, er i dag blitt oppnevnt som hovedsponsor for Melodi Grand Prix 2019 av den Europeiske Kringkastingsunionen (EBU). MyHeritage har, som arrangementets hovedsponsor, fått omfattende global assosiasjon og arrangement, media og digitale rettigheter i forbindelse med den kommende sangkonkurransen som vil finne sted i Tel Aviv. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20180926005471/no/ MyHeritages tjenester gjør det lett for hvem som helst, hvor som helst, å begi seg ut på en fascinerende oppdagelsesferd for å finne sine røtter. Ved hjelp av MyHeritage DNA-testen, MyHeritages integrerte slektstre-bygging-platform (Family Tree Builder) og samlinger bestående av ni milliarder historiske dokumenter, hjelper MyHeritage millioner av mennesker til å oppdage sine familiers fortid, og til å forstå hvordan de selv passer inn i den globale menneskelige mosaikken. De
Calldorado Selected as a Finalist of the 2018 Engage Awards26.9.2018 12:02 | Pressemelding
Calldorado ApS are proud to announce their selection as a finalist in the Best Employee Centric Strategy category of the Engage Awards 2018 – the only customer and employee engagement industry awards in the UK. Calldorado, a completely self-funded company, has grown exponentially in an incredibly short period of time, and this is reflected in the finalist list where it is shortlisted alongside giant brands such as Virgin Media and Bacardi. “We are delighted to be a finalist in the Best Employee Centric Strategy category of these prestigious awards. Our ethos from the very beginning has been to mix experienced expertise with young talent fresh from education. To nurture and develop the movers and shakers of tomorrow, whose careers will grow alongside the company. We operate on values of mutual trust and transparent sharing and listening. Everyone’s opinion has equal value, which inspires collaboration, and encourages thinking that leads to changes and product innovations which drive our
Slice Labs Raises $20M in Extended Series A to Globalize its On-Demand Insurance Cloud Platform26.9.2018 11:00 | Pressemelding
Slice Labs, a leading on-demand insurance cloud platform provider, today announced it has raised an additional $20 million in Series A funding, led by The Co-operators with participation from XL Innovate, Horizons, Munich Re/HSB Ventures, SOMPO, Veronorte, the investment arm of Grupo Sura, and JetBlue Technology Ventures. This sizable, extended round will be used to execute on the higher than planned global demand for Slice Insurance Cloud Services (ICS). Slice launched in 2016 with a mission to change, improve and redesign insurance. The company’s Insurance Cloud Services (ICS) is transforming traditional insurers into digitally-driven carriers by providing them with a platform that enables them to quickly ideate, experiment, test and deploy new, on-demand insurance products. Top global insurers have launched on-demand insurance products using ICS, and Slice will use this new financing to continue expanding its offering on a global scale. “The ICS platform is rapidly growing as insure
ZephyrTel Welcomes Vasona to Its Portfolio of Software Solutions Serving the Global Telecommunications Sector26.9.2018 10:01 | Pressemelding
ZephyrTel, an ESW Capital software company dedicated to serving the global telecommunications industry, is pleased to announce it has acquired Vasona Networks, a leader in network performance and edge computing software for mobile operators, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005376/en/ Mike Shinya, CEO of ZephyrTel (Photo: Business Wire) ZephyrTel is building a world-class telco practice, to provide a multi-solution and services proposition to the global telco industry and leading enterprises. The company’s primary objective is to offer software and SaaS solutions across telco companies IT estates; from infrastructure right through to customer experience. This, coupled with high levels of industry domain expertise, will enable it to offer consultancy on both business strategy and technology execution. Having already acquired several telecom software companies, ZephyrTel is currently
Hallstar Names Scott Hinkle as New Chief Financial Officer and Head of Global Shared Services26.9.2018 10:00 | Pressemelding
Scott J. Hinkle has joined Hallstar, the global specialty chemistry company, as Chief Financial Officer. He will be based in Hallstar’s corporate headquarters in Chicago, Illinois, reporting directly to Chairman and CEO, John J. Paro. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180926005216/en/ Hallstar Names Scott Hinkle as New Chief Financial Officer and Head of Global Shared Services (Photo: Business Wire) Founded in 1986, Hallstar has become widely recognized for its innovative expertise in the areas of photostability science, renewable plasticizers, eco-based actives, phthalate replacements, natural olive chemistry and polymer modification. The company boasts research and development, manufacturing, and sales operations in China, Italy, France, and Brazil, in addition to the United States. Hallstar recently announced a structural split into Hallstar Beauty and Hallstar Industrial, effective October 1, 2018. These two
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC26.9.2018 08:00 | Pressemelding
Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC). The survey results will be presented today as a late-breaking abstract (P3.01-108) at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada. The two most important treatment goals identified by those surveyed were increasing overall survival (OS) (77%), followed by quality of life (QoL) (69%), irrespective of the line of treatment. Findings show that more than half (55%) of physicians strongly preferred a treatment sequence that offers patients the maximum time on targeted treatments. Furthermore, physicians reported that there is a strong need for information on potential treatment resistance mutations before changing their current treatment pract